Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB-3222
- Development stage
- Preclinical
- Lead developer
- Vyome Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
VB-3222 is a topical wash-off anti-dandruff shampoo developed by Vyome Therapeutics for moderate adherent dandruff and scalp seborrheic dermatitis. The formulation contains zinc pyrithione and a proprietary synthetic medium-chain fatty-acid derivative used in Vyome's Molecular Replacement Therapeutics platform to potentiate antifungal activity against *Malassezia* species. In a 21-day, single-group clinical study in 25 participants with moderate dandruff, the product was reported to reduce adherent scalp flaking and pruritus and to be well tolerated. ([dovepress.com](https://www.dovepress.com/newly-developed-anti-dandruff-regimen-vb-3222-delivers-enhanced-sensor-peer-reviewed-fulltext-article-CCID))
Beyond the preview
Go deeper on VB-3222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB-3222.